Ortholan C, Auperin A, Mertens C, Le Caer H, Guigay J
Service d'oncologie - radiothérapie, centre hospitalier Princesse-Grace, 98000 Monaco, Monaco.
Département d'épidémiologie et de biostatistiques, institut Gustave-Roussy, Villejuif, France.
Cancer Radiother. 2018 Oct;22(6-7):640-643. doi: 10.1016/j.canrad.2018.06.008. Epub 2018 Aug 11.
Thirty percent of patients with head and neck cancer are over 70 years. Radiotherapy approach in elderly is a challenge. On one hand, radiotherapy side effects, as well as the number of sessions required, could be a burden. On the other hand, omission of local treatment is not an option due to the symptoms of the tumor. Patients in good general condition may receive standard fractionnated radiotherapy. For frail patients unsuitable for standard fractionated radiotherapy, more convenient shorter course of radiotherapy are commonly used. Physicians have to choose the best radiotherapy schedule according to the objective of the treatment. In case of palliative intend: hypofractionated radiotherapy delivered with a single short course could be recommanded. This course could be followed by other subsequent courses if the patient's condition improves during the treatment. For patients treated in curative intend, the choice of hypofractionation schedule depends on the general condition: split course hypofractionated radiotherapy for unfit patients, or accelerated radiotherapy with concomitant boost for fit patients. In all cases, a high-quality radiotherapy technique and appropriate supportive care are mandatory to minimize the side effects. The ELAN RT trial, soon to be completed, will rule on the non-inferiority of hypofractionated radiotherapy compared to standard radiotherapy for unfit patients.
30%的头颈癌患者年龄超过70岁。老年患者的放射治疗方法是一项挑战。一方面,放疗副作用以及所需疗程数量可能是一种负担。另一方面,由于肿瘤症状,不进行局部治疗并非选择。一般状况良好的患者可接受标准分割放疗。对于不适合标准分割放疗的体弱患者,通常采用更便捷的短程放疗。医生必须根据治疗目标选择最佳放疗方案。在姑息治疗目的情况下:可推荐单次短程的大分割放疗。如果患者在治疗期间病情改善,此疗程之后可接着进行其他后续疗程。对于以治愈为目的治疗的患者,大分割方案的选择取决于一般状况:不适合的患者采用分段大分割放疗,适合的患者采用加速放疗并同步推量。在所有情况下,高质量的放疗技术和适当的支持治疗对于将副作用降至最低是必不可少的。即将完成的ELAN RT试验将判定大分割放疗与标准放疗相比对不适合患者的非劣效性。